Cadonilimab Combined With Gem/Cis as First Line Therapy in Patients With Advanced ICC

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

November 24, 2022

Primary Completion Date

December 1, 2023

Study Completion Date

December 1, 2024

Conditions
Intrahepatic Cholangiocarcinoma
Interventions
DRUG

Cadonilimab+Gem/Cis

Cadonilimab (500mg, iv, Q3W, Day1) with gemcitabine(1000mg/m\^2, iv, Q3W, Day1and Day8) plus cisplatin(25mg/m\^2, iv, Q3W, Day1and Day8) up to 8 cycles followed by cadonilimab (500mg, iv, Q3W, Day1) plus capecitabine(1000 mg/m\^2 orally according to Body Surface Area (BSA),BID,Q3W,on Days 1-14)as maintenance therapy until disease progression or other discontinuation criteria, up to 24months.

Trial Locations (1)

20043

Eastern hepatobilliary surgery hospital, Shanghai

All Listed Sponsors
lead

Shen Feng

OTHER